BRANFORD, Conn., July 14, 2010 (GLOBE NEWSWIRE) -- CAS Medical Systems, Inc. (Nasdaq:CASM) today announced that a new study published in The Journal of Thoracic and Cardiovascular Surgery supports the association between decreased perioperative cerebral oxygenation values and poor outcomes after aortic arch surgery.

The study from researchers in the Departments of Anesthesiology and Cardiothoracic Surgery, at Mount Sinai School of Medicine, Mount Sinai Medical Center, New York, NY used CASMED's FORE-SIGHT ® Absolute Cerebral Oximeter to observe the affects of decreased intraoperative brain oxygen saturation in patients undergoing aortic arch surgery. Additionally, the researchers sought to identify absolute cerebral oxygen saturation threshold values that are predictive of organ dysfunction.

In this prospective study, the researchers found a statistically significant association between the accumulated duration of decreased cerebral tissue oxygen saturation (SctO2) and severe adverse outcomes (SAO), including major complications defined as death, stroke with persistent neurological deficits, new heart problems, respiratory failure, severe infection, delirium, new kidney failure, gastrointestinal complications and severe fluid retention. Using logistical regression, they found that the risk of SAO increased as a function of both accumulated duration of desaturation and decreasing SctO2 threshold value. As such, for every 5% decrease in the absolute SctO2 threshold, the incremental exposure time to achieve a given odds ratio (for SAO) decreased by half for SctO2 thresholds between 55% and 65%.

In addition, researchers also observed an association between lower absolute SctO2 values and prolonged time on mechanical ventilation, prolonged ICU stay and extended hospital length of stay, noting, "Patients who spent more than 30 minutes under the absolute threshold of 60% had an extended hospital stay of 4 days leading to an additional cost of $8,300."

Lead author, Gregory W. Fischer, M.D., Director of Adult Cardiothoracic Anesthesia and Associate Professor Anesthesiology & Cardiothoracic Surgery at Mount Sinai Medical Center, stated, "Surgical aortic arch repair is technically challenging and is associated with considerable morbidity and mortality. A potential advantage of absolute brain tissue oximetry is that threshold values may be more strongly associated with adverse outcomes than trend values. The results from the study lends further evidence to support the association between decreased perioperative cerebral oxygenation values and poor patient outcomes. While further studies will be helpful to show the impact of interventions at these thresholds, these results lend credibility to the emerging hypothesis that SctO2 monitoring may be useful as an indicator of overall organ perfusion and injury, and may lead to decreased hospital costs associated with major cardiac surgery. While it is too early to recommend specific target SctO2 values that should be maintained in different clinical settings. On a very preliminary basis, using the technology in this study in the clinical setting of thoracic aortic surgery, we believe that an SctO2 of 60% to 65% could represent this threshold value."


Fischer GW, Lin H-M, Krol M, Galati MF, DiLuozzo G, Griepp RB, Reich DL. Noninvasive cerebral oxygenation may predict outcome in patients undergoing aortic arch surgery. J Thorac Cardiovasc Surg. 2010 Jun 23. [Epub ahead of print].

Abstract available at .

About CASMED ® - Monitoring What's Vital

CAS Medical Systems, Inc. is a leading developer and manufacturer of medical devices for non-invasive patient monitoring. The Company's FORE-SIGHT Absolute Cerebral Oximeter is the only cerebral oximeter available with FDA clearance for non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation for all patients, regardless of age or weight. This information helps avert brain damage or death during surgery and in critical care situations by allowing clinicians to identify patients with dangerously low levels of cerebral oxygen and intervene to reverse the condition.

The Company's product lines include the high-acuity monitoring capabilities of the FORE-SIGHT Cerebral Oximeter; the bedside patient monitoring line of vital signs monitoring products, proprietary non-invasive blood pressure measurement technology, and supplies and service including blood pressure cuffs and products for neonatal intensive care. CASMED products are designed to meet the needs of a full spectrum of patient populations worldwide, ranging from adults to pediatrics and neonates.

For further information regarding CAS Medical Systems, Inc., visit the Company's website at .

The CAS Medical Systems, Inc. logo is available at

Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future financial performance of the Company are subject to many factors including, but not limited to, the customer acceptance of the products in the market, the introduction of competitive products and product development, the result of on-going litigation, working capital and availability of capital, commercialization and technological difficulties , the impact of actions and events involving key customers, vendors, lenders and competitors a nd other risks detailed in the Company's Form 10-K for the year ended December 31, 2009 and other subsequent Securities and Exchange Commission filings.

Such statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release the terms "anticipate", "believe", "estimate", "expect", "may", "objective", "plan", "possible", "potential", "project", "will" and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information or otherwise.
CONTACT:  CAS Medical Systems, Inc.          Susan Carron, Director of Corporate Communications          203-488-6056

company logo